Eurobio Scientific: COMMUNIQUÉ DU 24 SEPTEMBRE 2026 RELATIF AU DEPÔT D’UNE OFFRE PUBLIQUE DE RETRAIT SUIVIE D’UN RETRAIT OBLIGATOIRE VISANT LES ACTIONS DE LA SOCIÉTÉ

EB Development filed a proposed public buyout offer followed by a mandatory squeeze-out for Eurobio Scientific at €25.30 per share, valuing the remaining 992,846 shares (9.86% of capital) at approximately €25.1 million. The offer represents a 24.02% premium to Eurobio's September 16 closing price and will be open for 10 trading days if approved by the AMF. EB Development already owns 90.14% of Eurobio and plans to delist the in-vitro diagnostics and life-sciences company from Euronext Growth, while maintaining its existing strategy and employment policy.

Analysis

ALERS is now a cash-equivalent event-driven position rather than an operating-fundamentals exposure. With the bidder already above the squeeze-out threshold and a bank-guaranteed cash consideration, residual downside is principally procedural: AMF review, the independent expert’s fairness conclusion, or an unexpected challenge to valuation. The absence of a regulatory-clearance condition materially reduces execution risk, but Euronext Growth liquidity can make apparent screen prices unreliable before the formal offer window.

The relevant underwriting question is the annualized spread to €25.30 net of trading costs and the expected completion date, not Eurobio’s standalone diagnostic-growth outlook. A price below the consideration after AMF conformity offers a low-beta merger-arbitrage return over roughly 1-2 months; above it, there is no rational upside because the compulsory transfer fixes consideration. The sponsor’s prior purchases below the offer price do not establish a likelihood of a bump; instead, the unchanged consideration and fully specified financing indicate the buyer views the current price as its final economic commitment.

Contrarian risk is that minority holders focus on the headline premium while the independent expert applies DCF or transaction-comparable methods that identify a higher value, creating a delay and modest repricing optionality. That is not a base case: no competing-bid path is evident given the near-total ownership position, and a post-delisting reorganization means any long-term operational upside accrues privately. This transaction is more useful as a source of short-duration capital deployment than as a directional healthcare view.

Key Decisions for Investors

• Event-driven only: buy ALERS only at a discount sufficient to cover fees and target a minimum 8-10% annualized gross return to €25.30; use €24.85 as an indicative maximum entry for a roughly two-month completion, subject to actual offer calendar.
• Do not chase ALERS above €25.30 or establish a standalone healthcare-beta position; compulsory cash settlement caps payoff while liquidity can widen execution slippage.
• Set an AMF-conformity and independent-expert-report alert. Exit or reduce immediately if the expert finds consideration inadequate, the AMF requests material amendments, or the opening date moves beyond late November; these are the only credible catalysts for a spread widening.
• Size as a small-cap special situation with settlement/operational constraints, not as a core merger-arbitrage book position; lack of a public bidder instrument prevents a clean hedge and leaves residual French process risk.